Tim Jang

Tim Jang

Auto-generated profile, based on publicly available information

Tim Jang

University of Florida Dept of Medicine Gainesville, FL

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2025 in The Oncologist
Verified
Journal Article
Open access
TJTim Jang
Tim Jang
GKGeorge P Kim
George P Kim
TGThomas J George
Thomas J George
Background: Gastrointestinal (GI) malignancies remain the culprit behind a substantial portion of cancer-related mortality worldwide, and outcomes for patients with advanced or metastatic GI cancers remain poor despite continued efforts to improve care. In 2024, the ongoing clinical trials to optimize and improve GI cancer care showcased progress in molecular diagnostics, systemic therapies, and localized treatment approaches, providing hope for continued progress toward improved patient outcomes. Materials and Methods: This review summarizes selected updates in GI cancer care from the 2024 ASCO and ESMO Annual Meetings, including both positive and negative trials that, while not universally practice-changing, contribute to shaping GI cancer care, clinical management, or address key questions in the field. The selected trials cover early detection and diagnostic advances, perioperative management, metastatic disease management, and immune checkpoint inhibitor (ICI)’s emerging role in GI cancer. Results: Various clinical trials in perioperative management and their results continue to reshape or strengthen the current treatment paradigms. The use of ICIs for microsatellite instability-high colorectal cancer (CRC) presented a notable advancement with the potential to improve patient outcomes. Localized treatments such as thermal ablation appear to benefit some patients with CRC and liver metastases. Conclusions: The collection of trial results presented at the 2024 ASCO and ESMO Annual Meetings denote the ongoing efforts of the medical and scientific community for optimizing GI cancer care. The ongoing efforts of the GI cancer research and patient community provide hope for continued progress toward improved patient outcomes and new standards of care.

29 June 2026 in The Oncologist
Verified
Journal Article
Open access
TGThomas J George
Thomas J George
TLTuo Lin
Tuo Lin
INIbrahim Nassour
Ibrahim Nassour
SRSherise C Rogers
Sherise C Rogers
TJTim Jang
Tim Jang
SHSteven J Hughes
Steven J Hughes
Background: While neoadjuvant FOLFIRINOX is an effective regimen for pancreatic ductal adenocarcinoma (PDAC), toxicity frequently limits its use. Nanoliposomal irinotecan (nal-IRI) offers improved pharmacokinetic properties and may mitigate some of the side effects. We conducted a multi-institutional, phase II study to evaluate the safety and clinical activity of neoadjuvant NALIRIFOX (nal-IRI, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with resectable and borderline resectable (R/BR) PDAC. Methods: Patients with untreated R/BR PDAC received eight cycles of neoadjuvant NALIRIFOX. The primary endpoint was the 30-day post-operative major complication rate among resected patients. Secondary endpoints included treatment completion rate, R0 resection rate, objective response rate (ORR), biochemical (CA19-9) and radiographic responses, nodal downstaging, and quality of life (QoL by FACT-G). Results: Of the 45 enrolled patients, 73% completed all eight cycles of neoadjuvant NALIRIFOX. 34 patients (76%) underwent attempted surgery, of whom 29 (64%) had complete resection (15 BR patients and 14 R patients). The 30-day post-operative major complication rate was 10% (95% CI, 2.2–27%, p = 0.012), meeting the pre-specified threshold. R0 resection was achieved in 90% of resected patients. The radiographic ORR was 45% (95% CI, 29–62%), and the clinical benefit rate was 73% (95% CI, 58–85%). Conclusion: Neoadjuvant NALIRIFOX is a safe and active regimen in R/BR PDAC with a low post-operative complication rate, high treatment completion and R0 resection rates, and meaningful clinical responses. These findings support further investigation of NALIRIFOX as part of a total neoadjuvant therapy (TNT) approach in PDAC. [ClinicalTrials.gov identifier: NCT03483038].

31 December 2024 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
TJTim Jang
Tim Jang
RBRachel D Burnside
Rachel D Burnside
JCJoanna Chaffin
Joanna Chaffin
RSRobert Seifert
Robert Seifert
JHJohn W. Hiemenz
John W. Hiemenz

1 July 2025 in Cancer Genetics
Verified
Journal Article
Closed access
PMPatrick Maher
Patrick Maher
TJTim Jang
Tim Jang
RVRuben Ruiz Vega
Ruben Ruiz Vega
JMJennifer Miatech
Jennifer Miatech
GMGabriela Bastidas Mora
Gabriela Bastidas Mora
RBRachel D Burnside
Rachel D Burnside